Cargando…

Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac

OBJECTIVE: To quantitatively characterize the dosimetric effects of long on-couch time in prostate cancer patients treated with adaptive ultra-hypofractionated radiotherapy (UHF-RT) on 1.5-Tesla magnetic resonance (MR)-linac. MATERIALS AND METHODS: Seventeen patients consecutively treated with UHF-R...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lin-Rui, Tian, Yuan, Wang, Ming-Shuai, Xia, Wen-Long, Qin, Shi-Rui, Song, Yong-Wen, Wang, Shu-Lian, Tang, Yu, Fang, Hui, Tang, Yuan, Qi, Shu-Nan, Yan, Ling-Ling, Liu, Yue-Ping, Jing, Hao, Chen, Bo, Xing, Nian-Zeng, Li, Ye-Xiong, Lu, Ning-Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893501/
https://www.ncbi.nlm.nih.gov/pubmed/36741014
http://dx.doi.org/10.3389/fonc.2023.1039901
_version_ 1784881541408620544
author Gao, Lin-Rui
Tian, Yuan
Wang, Ming-Shuai
Xia, Wen-Long
Qin, Shi-Rui
Song, Yong-Wen
Wang, Shu-Lian
Tang, Yu
Fang, Hui
Tang, Yuan
Qi, Shu-Nan
Yan, Ling-Ling
Liu, Yue-Ping
Jing, Hao
Chen, Bo
Xing, Nian-Zeng
Li, Ye-Xiong
Lu, Ning-Ning
author_facet Gao, Lin-Rui
Tian, Yuan
Wang, Ming-Shuai
Xia, Wen-Long
Qin, Shi-Rui
Song, Yong-Wen
Wang, Shu-Lian
Tang, Yu
Fang, Hui
Tang, Yuan
Qi, Shu-Nan
Yan, Ling-Ling
Liu, Yue-Ping
Jing, Hao
Chen, Bo
Xing, Nian-Zeng
Li, Ye-Xiong
Lu, Ning-Ning
author_sort Gao, Lin-Rui
collection PubMed
description OBJECTIVE: To quantitatively characterize the dosimetric effects of long on-couch time in prostate cancer patients treated with adaptive ultra-hypofractionated radiotherapy (UHF-RT) on 1.5-Tesla magnetic resonance (MR)-linac. MATERIALS AND METHODS: Seventeen patients consecutively treated with UHF-RT on a 1.5-T MR-linac were recruited. A 36.25 Gy dose in five fractions was delivered every other day with a boost of 40 Gy to the whole prostate. We collected data for the following stages: pre-MR, position verification-MR (PV-MR) in the Adapt-To-Shape (ATS) workflow, and 3D-MR during the beam-on phase (Bn-MR) and at the end of RT (post-MR). The target and organ-at-risk contours in the PV-MR, Bn-MR, and post-MR stages were projected from the pre-MR data by deformable image registration and manually adapted by the physician, followed by dose recalculation for the ATS plan. RESULTS: Overall, 290 MR scans were collected (85 pre-MR, 85 PV-MR, 49 Bn-MR and 71 post-MR scans). With a median on-couch time of 49 minutes, the mean planning target volume (PTV)-V(95%) of all scans was 97.83 ± 0.13%. The corresponding mean clinical target volume (CTV)-V(100%) was 99.93 ± 0.30%, 99.32 ± 1.20%, 98.59 ± 1.84%, and 98.69 ± 1.85%. With excellent prostate-V(100%) dose coverage, the main reason for lower CTV-V(100%) was slight underdosing of seminal vesicles (SVs). The median V(29 Gy) change in the rectal wall was -1% (-20%–17%). The V(29 Gy) of the rectal wall increased by >15% was observed in one scan. A slight increase in the high dose of bladder wall was noted due to gradual bladder growth during the workflow. CONCLUSIONS: This 3D-MR–based dosimetry analysis demonstrated clinically acceptable estimated dose coverage of target volumes during the beam-on period with adaptive ATS workflow on 1.5-T MR-linac, albeit with a relatively long on-couch time. The 3-mm CTV-PTV margin was adequate for prostate irradiation but occasionally insufficient for SVs. More attention should be paid to restricting high-dose RT to the rectal wall when optimizing the ATS plan.
format Online
Article
Text
id pubmed-9893501
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98935012023-02-03 Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac Gao, Lin-Rui Tian, Yuan Wang, Ming-Shuai Xia, Wen-Long Qin, Shi-Rui Song, Yong-Wen Wang, Shu-Lian Tang, Yu Fang, Hui Tang, Yuan Qi, Shu-Nan Yan, Ling-Ling Liu, Yue-Ping Jing, Hao Chen, Bo Xing, Nian-Zeng Li, Ye-Xiong Lu, Ning-Ning Front Oncol Oncology OBJECTIVE: To quantitatively characterize the dosimetric effects of long on-couch time in prostate cancer patients treated with adaptive ultra-hypofractionated radiotherapy (UHF-RT) on 1.5-Tesla magnetic resonance (MR)-linac. MATERIALS AND METHODS: Seventeen patients consecutively treated with UHF-RT on a 1.5-T MR-linac were recruited. A 36.25 Gy dose in five fractions was delivered every other day with a boost of 40 Gy to the whole prostate. We collected data for the following stages: pre-MR, position verification-MR (PV-MR) in the Adapt-To-Shape (ATS) workflow, and 3D-MR during the beam-on phase (Bn-MR) and at the end of RT (post-MR). The target and organ-at-risk contours in the PV-MR, Bn-MR, and post-MR stages were projected from the pre-MR data by deformable image registration and manually adapted by the physician, followed by dose recalculation for the ATS plan. RESULTS: Overall, 290 MR scans were collected (85 pre-MR, 85 PV-MR, 49 Bn-MR and 71 post-MR scans). With a median on-couch time of 49 minutes, the mean planning target volume (PTV)-V(95%) of all scans was 97.83 ± 0.13%. The corresponding mean clinical target volume (CTV)-V(100%) was 99.93 ± 0.30%, 99.32 ± 1.20%, 98.59 ± 1.84%, and 98.69 ± 1.85%. With excellent prostate-V(100%) dose coverage, the main reason for lower CTV-V(100%) was slight underdosing of seminal vesicles (SVs). The median V(29 Gy) change in the rectal wall was -1% (-20%–17%). The V(29 Gy) of the rectal wall increased by >15% was observed in one scan. A slight increase in the high dose of bladder wall was noted due to gradual bladder growth during the workflow. CONCLUSIONS: This 3D-MR–based dosimetry analysis demonstrated clinically acceptable estimated dose coverage of target volumes during the beam-on period with adaptive ATS workflow on 1.5-T MR-linac, albeit with a relatively long on-couch time. The 3-mm CTV-PTV margin was adequate for prostate irradiation but occasionally insufficient for SVs. More attention should be paid to restricting high-dose RT to the rectal wall when optimizing the ATS plan. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9893501/ /pubmed/36741014 http://dx.doi.org/10.3389/fonc.2023.1039901 Text en Copyright © 2023 Gao, Tian, Wang, Xia, Qin, Song, Wang, Tang, Fang, Tang, Qi, Yan, Liu, Jing, Chen, Xing, Li and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gao, Lin-Rui
Tian, Yuan
Wang, Ming-Shuai
Xia, Wen-Long
Qin, Shi-Rui
Song, Yong-Wen
Wang, Shu-Lian
Tang, Yu
Fang, Hui
Tang, Yuan
Qi, Shu-Nan
Yan, Ling-Ling
Liu, Yue-Ping
Jing, Hao
Chen, Bo
Xing, Nian-Zeng
Li, Ye-Xiong
Lu, Ning-Ning
Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac
title Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac
title_full Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac
title_fullStr Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac
title_full_unstemmed Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac
title_short Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac
title_sort assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-tesla mr-linac
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893501/
https://www.ncbi.nlm.nih.gov/pubmed/36741014
http://dx.doi.org/10.3389/fonc.2023.1039901
work_keys_str_mv AT gaolinrui assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT tianyuan assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT wangmingshuai assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT xiawenlong assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT qinshirui assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT songyongwen assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT wangshulian assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT tangyu assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT fanghui assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT tangyuan assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT qishunan assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT yanlingling assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT liuyueping assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT jinghao assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT chenbo assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT xingnianzeng assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT liyexiong assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac
AT luningning assessmentofdelivereddoseinprostatecancerpatientstreatedwithultrahypofractionatedradiotherapyon15teslamrlinac